Profound Medical EBITDA
The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Profound Medical (PRN.TO) as of Oct 14, 2026 is -41.98 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -33.06 M USD — a change of 26.96% (lower).
Get this data via API
Financial Data API
EBITDA
-41.98 MUSD
YoY
26.96%
Last updated:
The Profound Medical EBITDA history
3 Years
10 Years
25 Years
Max
| YEAR | EBITDA | YoY |
|---|---|---|
| -41.98 MUSD | +26.96% | |
| -33.06 MUSD | +15.54% | |
| -28.62 MUSD | -10.93% | |
| -32.13 MUSD | +5.24% | |
| -30.53 MUSD | +61.84% | |
| -18.86 MUSD | -1.29% | |
| -19.11 MUSD | +31.52% | |
| -14.53 MUSD | -11.96% | |
| -16.50 MUSD | +4.78% | |
| -15.75 MUSD | +32.12% | |
| -11.92 MUSD | +144.33% | |
| -4.88 MUSD | — |
Profound Medical Stock analysis
Frequently Asked Questions about Profound Medical stock
EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Profound Medical is -41.98 M USD in 2025.
EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Profound Medical changed from -33.06 M USD to -41.98 M USD, representing a 26.96% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Profound Medical since 2006 – with annual values, charts, and detailed analysis.
EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.
EBITDA = EBIT + Depreciation & Amortization
EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Profound Medical historically and in real time.
Income Statement — Profound Medical
All Key Metrics — Profound Medical
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth